Tags : Inarigivir

Spring Bank Discontinues the Development of Inarigivir to Treat Patients

Shots: Spring Bank has discontinued the development of Inarigivir soproxil due to the occurrence of one patient death in its P-IIb CATALYST study The discontinuation allows Spring Bank to focus on immuno-oncology & inflammation including its SB 11285 IV STING agonist clinical program in oncology, STING antagonist for inflammatory diseases, and its STING agonist ADC […]Read More